The Quantellect read.As of Nov 20, 2026, 4 active firms cover Novavax Inc: 2 rate it Buy or better, 1 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets range widely, $8.00 to $19.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $12.00 sits 55% above the current $7.72. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.35 next quarter toward $-0.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy250%
Neutral125%
Sell125%
Strong Sell00%
Based on 4 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$12.00
+55.4% upside
Average target across 3 active firms as of Nov 20, 2026 vs $7.72 current
Highest Target$19.00
Average Target$12.00
Lowest Target$8.00
Detailed analyst forecasts for NVAX
Showing 1–3 of 3 named analysts shown · 4 active firms in the rating projection
As of Nov 20, 2026, 2 of 4 active firms rate NVAX a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NVAX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.35
Range $-0.45 – $-0.24 · 3 analysts · +489% YoY
Next period, 3 analysts expect Novavax Inc to earn $-0.35 a share (range $-0.45 – $-0.24), versus $-0.06 a year earlier. Full-year consensus is $-0.05, growing to $-0.45 the year after.
REVENUE · NEXT QUARTER
$35.8M
Range $28.4M – $43.2M · 3 analysts · -74% YoY
Revenue is expected to reach $35.8M (range $28.4M – $43.2M), -74.3% year-over-year. Full-year consensus is $473.1M, rising to $246.1M next year.
Top analysts covering Novavax Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NVAX.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$18.00+133.2% to target
Overall win rate
49%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #171
Sell
$6.00-22.3% to target
Overall win rate
48%
+ Follow
#3
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
$18.00+133.2% to target
Overall win rate
35%
+ Follow
#4
Sean Lee
HC Wainwright & Co. · Rank #344
Buy
$10.00+29.5% to target
Overall win rate
40%
+ Follow
#5
Thomas Shrader
BTIG · Rank #553
Buy
$19.00+146.1% to target
Overall win rate
32%
+ Follow
NVAX stock forecast FAQ
What is NVAX's average 12-month price target?+
The 3 active firms with a live target average $12.00 for Novavax Inc over the next 12 months, ranging from a $19.00 high to a $8.00 low, as of Nov 20, 2026.
Is NVAX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 20, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NVAX?+
The Street-high target is $19.00 (BTIG), and the Street-low is $8.00 (Citigroup). The average of all 3 active-firm targets is $12.00.
How many active Wall Street firms cover NVAX?+
4 active firms have a recognized rating on Novavax Inc as of Nov 20, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NVAX?+
Among analysts who currently cover NVAX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $18.00 target.
What is Novavax Inc's projected EPS for next quarter?+
The consensus estimate is $-0.35 per share (range $-0.45 – $-0.24) across 3 analysts. Full-year EPS is projected at $-0.05, rising to $-0.45 the following year.
How much revenue is Novavax Inc expected to report next quarter?+
Consensus revenue is $35.8M (range $28.4M – $43.2M). Full-year revenue is projected at $473.1M, growing to $246.1M next year.
Have analysts been upgrading or downgrading NVAX lately?+
As of Nov 20, 2026, 2 of 4 active firms rate NVAX a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NVAX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.